GLP-1 receptor agonists for the treatment of steatotic liver disease
Researchers from Centre for Liver Research have published a review article in Hepatology Communications highlighting the promising role of GLP-1 receptor agonists in the treatment of steatotic liver disease (SLD).
SLD is a chronic liver condition caused by alcohol overconsumption and metabolic disturbances such as obesity and insulin resistance, leading to fat accumulation in the liver, inflammation, and eventually fibrosis.
GLP-1 receptor agonists, commonly known under brand names like Ozempic and Wegovy, are synthetic analogs of the gut hormone GLP-1, which have demonstrated effects on weight loss, blood sugar regulation, and reduced alcohol intake. These properties position them as a potential tool in managing SLD. In their article, the researchers detail how these medications can both directly and indirectly reduce liver fat, inflammation, and fibrosis, potentially improving disease outcomes.
While the results are promising, the study emphasizes that the direct effects on liver fibrosis remain unclear. However, the indirect effects, such as weight loss and improved metabolic health, are highlighted as critical factors in reducing the risk of liver-related complications. This new knowledge paves the way for future SLD treatments and holds the potential to significantly enhance the quality of life for many patients worldwide.
The article is available in Hepatology Communications
